WOCKPHARMA2018-01-012018-03-31in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2018-01-012018-03-31in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2018-01-012018-03-31in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2018-01-012018-03-31in-bse-fin:FourOperatingExpenses02Member WOCKPHARMA2018-01-012018-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2018-01-012018-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2018-01-012018-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2018-01-012018-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares WOCKPHARMA 2017-04-01 2018-03-31 2018-04-18 INR Crores Yearly Single segment Pharmaceuticals 2018-01-01 2018-03-31 Audited Consolidated 10182600000.00 -84100000.00 10098500000.00 2558300000.00 2210400000.00 -119800000.00 2201000000.00 649700000.00 382100000.00 3393600000.00 11275300000.00 -1176800000.00 0.00 -1176800000.00 309400000.00 42900000.00 352300000.00 0.00 -1529100000.00 0.00 0.00 0.00 0.00 -1529100000.00 727800000.00 -801300000.00 -1545500000.00 16400000.00 -945400000.00 144100000.00 553200000.00 5 -13.97 -13.97 0.00 0.00 -13.97 -13.97 Notes To Consolidated Results:-ttttttt n n1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 04, 2018. The statutory auditors have expressed an unmodified audit opinion with respect to the Audited Financial Results of the Company for the quarter/year ended March 31, 2018. n n2) These Consolidated Results relate to Wockhardt Limited (the Holding Company) and its Subsidiaries (together constitute the Group) and are prepared by applying Ind AS 110 Consolidated Financial Statements. n n3) During the year, the Company has allotted 82,425 equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options. n n4) Exceptional item: During the year ended March 31, 2018, the on-going commercial litigation between the Company and two of its subsidiaries namely Wockhardt UK Holdings Limited and CP Pharmaceuticals Limited (CP) in relation to a supply contract with Cephalon Inc, (Cephalon) an affiliate of Teva Pharmaceuticals USA, Inc. (Teva) before the High Court in London, United Kingdom, was settled at cost of GBP 43 million to the Group. nThe High Court has accepted the settlement between the parties and a Consent Order was issued on June 21, 2017. Pursuant to this settlement the ongoing litigation stands closed. n n5) Subject to the approval of shareholders at the annual general meeting, Board of Directors have recommended dividend of 0.01% (at the rate of Rs. 0.0005 per share of Rs. 5/- each) on 475,659,941 Non-convertible Cumulative Redeemable Preference shares of Rs. 5/- each and 121,454,927 Optionally Convertible Cumulative Redeemable Preference Shares of Rs. 5/- each aggregating to Rs. 298,557/- n n6) Key Financials on Standalone basis: nttttt (Rs in Crore) nParticularst 3 MONTH 3 MONTHS 3 MONTHS YEAR YEAR n ENDED ENDED ENDED ENDED ENDED n 31/03/2018 31/12/2017 31/03/2017 31/03/2018 31/03/2017 n Auditedt Unaudited Audited t Audited Audited n nNet Sales / Income from operationst913.34t 535.12t540.54t 2477.29t 2297.52 nProfit / (Loss) Before Taxt 269.87 t (37.68)t 1.61t 103.92 118.78 nProfit / (Loss) After Taxt 172.44 t (27.52)t (5.91) t 68.66t 137.12 n nNote: The Audited stand alone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com ) and also on the Company's website www.wockhardt.com. n n7) Figures for the quarter ended March 31, 2018 and March 31, 2017 are the balancing figures between the audited figures in respect of the full financial year and the reviewed figures upto the third quarter of the relevant financial year. n n8) The Group is exclusively into Pharmaceutical business Segment. n n9) For List of Subsidiaries as on March 31, 2018 please refer below list. n n10) Previous periods / year figures have been recast / regrouped to conform to the current period's presentation. n n11) List of Subsidiaries as on March 31, 2018 refer attached pdf. 2017-04-01 2018-03-31 Audited Consolidated 39369000000.00 1202300000.00 40571300000.00 8675300000.00 7514700000.00 1785300000.00 9370600000.00 2554900000.00 1495300000.00 12004800000.00 43400900000.00 -2829600000.00 -3581900000.00 -6411500000.00 507900000.00 -250900000.00 257000000.00 0.00 -6668500000.00 0.00 0.00 0.00 0.00 -6668500000.00 1393600000.00 -5274900000.00 -6083000000.00 -585500000.00 -4912800000.00 -362100000.00 553200000.00 5 27968300000.00 -55.01 -55.01 0.00 0.00 -55.01 -55.01 Exchange fluctuation (gain) / loss -238500000.00 Other Expenses 3632100000.00 Exchange fluctuation (gain) / loss -572600000.00 Other Expenses 12577400000.00 0.00 0.00 0.00